Mike Danielson, Ph.D., has spent 17 years immersed in immuno-oncology drug development and discovery. He joins HiberCell from Biothera Pharmaceuticals, Inc., where he served in key roles driving the development of Imprime. He was part of a team responsible for the characterization and analysis of complex carbohydrate polymers and he contributed to process chemistry and manufacturing. He also led a discovery effort aimed at finding second generation carbohydrate based immunomodulators, novel vaccine platforms, and various glucan mAb conjugates. His career began at 3M Pharmaceuticals where he designed and synthesized small molecule imidazoquinoline and pyrazoloquinoline Toll Like Receptor (TLR) 7/8 agonists.
The TLR platform was purchased by Coley Pharmaceuticals in 2006 at which point Mike made his transition to his second immunomodulation company, Biothera. He quickly transitioned from the world of small molecule heterocycles into that of carbohydrate polymer-based biologics.
Mike earned his B.A. in chemistry with honors from Macalester College while performing research in the laboratories of Dr. Rebecca C. Hoye. He then earned his Ph.D. at the University of Minnesota. He is the author of over 25 peer reviewed publications, issued patents, and patent applications.